https://www.nature.com/articles/d41586-023-01610-z Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * Log in * Explore content * About the journal * Publish with us * Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article * NEWS * 15 May 2023 How one man's rare Alzheimer's mutation delayed the onset of disease Genetic resilience found in a person predisposed to early-onset dementia could potentially lead to new treatments. * Sara Reardon 1. Sara Reardon View author publications You can also search for this author in PubMed Google Scholar * Twitter * Facebook * Email You have full access to this article via your institution. Download PDF [d41586-023] Electron microscope image showing an amyloid plaque and tau fibres (dark pink lines) in the brain of a person with Alzheimer's disease. Amyloid plaques are insoluble aggregates of beta-amyloid protein. Credit: Thomas Deerink/NCIR/SPL Researchers have identified a man with a rare genetic mutation that protected him from developing dementia at an early age. The finding, published on 15 May in Nature Medicine^1, could help researchers to better understand the causes of Alzheimer's disease and potentially lead to new treatments. For nearly 40 years, neurologist Francisco Lopera at the University of Antioquia in Medellin, Colombia, has been following an extended family whose members develop Alzheimer's in their forties or earlier. Many of the approximately 6,000 family members carry a genetic variant called the paisa mutation that inevitably leads to early-onset dementia. But now, Lopera and his collaborators have identified a family member with a second genetic mutation -- one that protected him from dementia until age 67. "Reading that paper made the hair on my arms stand up," says neuroscientist Catherine Kaczorowski at the University of Michigan in Ann Arbor. "It's just such an important new avenue to pursue new therapies for Alzheimer's disease." Mutated protein Lopera and his colleagues analysed the genomes and medical histories of 1,200 Colombians with the paisa mutation, which causes dementia around ages 45--50. They identified the man with the second mutation when he was 67 and had only mild cognitive impairment. When the researchers scanned his brain, they found high levels of the sticky protein complexes known as amyloid plaques, which are thought to kill neurons and cause dementia, as well as a protein called tau that accumulates as the disease progresses. The brain looked like that of a person with severe dementia, says study co-author Joseph Arboleda, an ophthalmologist at Harvard Medical School in Boston. But one small brain area called the entorhinal cortex, which coordinates skills such as memory and navigation, had low levels of tau. The researchers found that the man had a mutation in a gene coding for a protein called reelin, which is associated with brain disorders including schizophrenia and autism. Little is known about reelin's role in Alzheimer's, so the researchers genetically engineered mice with the same mutation. In mice, the mutated form of reelin caused the tau protein to be chemically modified, limiting its ability to cluster around neurons. The study challenges the theory that Alzheimer's disease is primarily driven by amyloid plaques, which are the targets of several drugs recently approved by the US Food and Drug Administration. The drugs effectively remove amyloid from the brain, but lead to only a moderate improvement in rates of cognitive decline. The fact that the man stayed mentally healthy for so long despite the many amyloid plaques in his brain suggests that Alzheimer's is more complicated, says Yadong Huang, a neurologist at the Gladstone Institutes in San Francisco, California. He suggests that there could be multiple subtypes of Alzheimer's, only some of which are driven by amyloid. "We do need different pathways to really finally deal with this disease," he says. The link to tau, he says, is especially promising because it suggests that tau plays a role in mental decline. Several therapies targeting tau are currently in clinical trials. Shared mechanisms Lopera says that the reelin mutation is extremely rare in the general population, but that his team is now looking for this and other mutations among people with the paisa mutation. The man's sister, who had both the paisa and reelin mutations, began developing cognitive impairment at age 58 and severe dementia at 64 -- later than average for someone with the paisa mutation. The authors say that she had experienced head injuries and had other disorders that could have contributed to her developing dementia earlier than her brother. Arboleda notes that the mutated reelin protein binds to the same receptors as a protein called APOE, which is also associated with Alzheimer's disease in people who do not have the paisa mutation. In 2019, the same group had identified a woman with the paisa mutation who developed dementia 30 years later than average, owing to a mutation in APOE^2. Like the man in the latest study, the woman's brain contained much higher levels of amyloid than would be expected in someone with so few Alzheimer's symptoms. "It's really cool because it's telling us there's some shared mechanisms," Kaczorowski says. Reelin and APOE compete to bind to the receptor, and the two findings suggest that either a stronger reelin protein or a weaker APOE protein can protect the brain against the disease. Arboleda says this suggests that therapies targeting reelin or APOE might be even more effective in sporadic Alzheimer's cases, which tend to be less aggressive and progress more slowly than the early-onset type that the Colombian family experiences. As with many people with Alzheimer's, the man's hippocampus -- a brain region controlling learning and memory -- was smaller than average at the time of his death, suggesting that it was degenerating. But because his cognitive abilities remained relatively intact, Kaczorowski says, neurons in other parts of the brain might have repurposed themselves to make up for the damage. Knowing whether that happens, she adds, could help to inform future therapeutic strategies. "The vast majority of research focuses on why some people have Alzheimer's, very few are on conditions where a factor can go against this disease," says Huang. He says that further research is needed to pin down the mechanism through which reelin and APOE affect tau, and whether targeting these proteins could help people with Alzheimer's who do not have the paisa mutation. "This is one of those few cases that really opens the door for anti-Alzheimer's research." doi: https://doi.org/10.1038/d41586-023-01610-z References 1. Lopera, F. et al. Nature Med. https://doi.org/10.1038/ s41591-023-02318-3 (2023). Article Google Scholar 2. Arboleda-Velasquez, J.F. et al. Nat Med 25, 1680-1683 (2019). Article PubMed Google Scholar Download references Related Articles * [d41586-023] More Alzheimer's drugs head for FDA review: what scientists are watching * [d41586-023] This is how an Alzheimer's gene ravages the brain * [d41586-023] Are infections seeding some cases of Alzheimer's disease? * [d41586-023] Is 'friendly fire' in the brain provoking Alzheimer's disease? * Pioneering Alzheimer's study in Colombia zeroes in on enigmatic protein * Frustrated Alzheimer's researchers seek better lab mice Subjects * Genetics * Neuroscience * Brain Latest on: Genetics Human pangenome supports analysis of complex genomic regions Human pangenome supports analysis of complex genomic regions News & Views Forum 10 MAY 23 Guide to potato genome could make for a bigger spud crop Guide to potato genome could make for a bigger spud crop Research Highlight 10 MAY 23 Increased mutation and gene conversion within human segmental duplications Increased mutation and gene conversion within human segmental duplications Article 10 MAY 23 Neuroscience Chronic pain: try new routes to more tailored treatments Correspondence 16 MAY 23 Brain imaging: fMRI advances make scans sharper and faster Brain imaging: fMRI advances make scans sharper and faster Technology Feature 15 MAY 23 Brain-based treatment for menopausal hot flushes approved by FDA Brain-based treatment for menopausal hot flushes approved by FDA News 15 MAY 23 Brain Brain imaging: fMRI advances make scans sharper and faster Brain imaging: fMRI advances make scans sharper and faster Technology Feature 15 MAY 23 Alzheimer's drug donanemab: what promising trial means for treatments Alzheimer's drug donanemab: what promising trial means for treatments News 04 MAY 23 How menopause reshapes the brain How menopause reshapes the brain News Feature 03 MAY 23 Nature Careers Jobs * Principal Scientist - Oral Biologics About the Department ... Lexington, Massachusetts Novo Nordisk [] * W2 professorship for ophthalmology (m/f/d) At the University Medical Center Greifswald, a legal entity of the University of Greifswald, a W2 professorship for ophthalmology (m/f/d) in the Cl... Greifswald, Mecklenburg-Vorpommern (DE) Universitatsmedizin Greifswald KoR [] * Postdoctoral scholarship, 2 years, in plant developmental biology A two-year postdoctoral scholarship within the project "Analysis of miRNA function during embryo development in Norway spruce." Umea, Sweden Umea Plant Science Centre, Swedish University of Agricultural Sciences [] * Postdoctoral Research Scientist in Bioinformatics and Neuroscience Postdoctoral Research Scientist position for large-scale analysis of genomic and multi-omic datasets on Alzheimer's Disease and related disorders New York City, New York (US) Columbia University Taub Institute [] * Postdoctoral Associate- Nutrition Summary The Children's Nutrition Research Center (CNRC) at Baylor College of Medicine invites applications for a Postdoctoral Associate in Pediatri... Houston, Texas (US) Baylor College of Medicine (BCM) [] You have full access to this article via your institution. Download PDF Related Articles * [d41586-023] More Alzheimer's drugs head for FDA review: what scientists are watching * [d41586-023] This is how an Alzheimer's gene ravages the brain * [d41586-023] Are infections seeding some cases of Alzheimer's disease? * [d41586-023] Is 'friendly fire' in the brain provoking Alzheimer's disease? * Pioneering Alzheimer's study in Colombia zeroes in on enigmatic protein * Frustrated Alzheimer's researchers seek better lab mice Subjects * Genetics * Neuroscience * Brain Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Journal Metrics * Awards * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Language editing services * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio * About us * Press releases * Press office * Contact us Discover content * Journals A-Z * Articles by subject * Nano * Protocol Exchange * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Nature Research Academies * Research Solutions Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Career development * Nature Careers * Nature Conferences * Nature events Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Korea * Nature Middle East * Privacy Policy * Use of cookies * Manage cookies/Do not sell my data * Legal notice * Accessibility statement * Terms & Conditions * California Privacy Statement Springer Nature (c) 2023 Springer Nature Limited